Table of Contents
Journal of Amino Acids
Volume 2013 (2013), Article ID 429847, 5 pages
http://dx.doi.org/10.1155/2013/429847
Research Article

An Evaluation of Interindividual Responses to the Orally Administered Neurotransmitter β-Alanine

1Department of Medicine (Neurology), Dalhousie University, Halifax, NS, Canada B3M 3R4
2Department of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada B3M 3R4
3Department of Chemistry, Dalhousie University, Halifax, NS, Canada B3M 3R4

Received 29 November 2012; Accepted 6 June 2013

Academic Editor: Hari S. Sharma

Copyright © 2013 Sarah MacPhee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. F. Weaver, “Designing future drugs for the treatment of intractable epilepsy,” Advances in Neurology, vol. 97, pp. 429–434, 2006. View at Google Scholar · View at Scopus
  2. C. Y. K. Tan, D. Wainman, and D. F. Weaver, “N-, α-, and β-substituted 3-aminopropionic acids: design, syntheses and antiseizure activities,” Bioorganic and Medicinal Chemistry, vol. 11, no. 1, pp. 113–121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. F. Weaver, P. Milne, C. Tan, and J. Carran, Anti-Epileptogenic Agents, U.S. Patent No. 6, 306, 909, issued October 23, 2001.
  4. F. V. DeFeudis and R. Martin Del Rio, “Is β-alanine an inhibitory neurotransmitter?” General Pharmacology, vol. 8, no. 3, pp. 177–180, 1977. View at Google Scholar · View at Scopus
  5. K. E. Tiedje, K. Stevens, S. Barnes, and D. F. Weaver, “β-alanine as a small molecule neurotransmitter,” Neurochemistry International, vol. 57, no. 3, pp. 177–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. R. Scriver, S. Pueschel, and E. Davies, “Hyper-β-alaninemia associated with β-aminoaciduria and γ-aminobutyricaciduaia, somnolence and seizures,” The New England Journal of Medicine, vol. 274, no. 12, pp. 635–643, 1966. View at Google Scholar · View at Scopus
  7. R. C. Harris and M. Dunnett, UK Patent 10-12-99 05965596, 1997.
  8. T. Stellingwerff, M. Boit, and P. Res, “Nutritional strategies to optimize training and racing in middle-distance athletes,” Journal of Sports Sciences, vol. 25, supplement 1, pp. 17–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Stout, J. T. Cramer, R. F. Zoeller et al., “Effects of β-alanine supplementation on the onset of neuromuscular fatigue and ventilatory threshold in women,” Amino Acids, vol. 32, no. 3, pp. 381–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Jordan, J. Lukaszuk, M. Misic, and J. Umoren, “Effect of beta-alanine supplementation on the onset of blood lactate accumulation (OBLA) during treadmill running: pre/post 2 treatment experimental design,” Journal of the International Society of Sports Nutrition, vol. 7, article 20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Stout, B. S. Sue, A. E. Smith et al., “The effect of beta-alanine supplementation on neuromuscular fatigue in elderly (55-92 Years): a double-blind randomized study,” Journal of the International Society of Sports Nutrition, vol. 5, article 21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. C. Harris, M. J. Tallon, M. Dunnett et al., “The absorption of orally supplied β-alanine and its effect on muscle carnosine synthesis in human vastus lateralis,” Amino Acids, vol. 30, no. 3, pp. 279–289, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Derave, M. S. Özdemir, R. C. Harris et al., “β-alanine supplementation augments muscle carnosine content and attenuates fatigue during repeated isokinetic contraction bouts in trained sprinters,” Journal of Applied Physiology, vol. 103, no. 5, pp. 1736–1743, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. V. J. Burroughs, R. W. Maxey, and R. A. Levy, “Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment,” Journal of the National Medical Association, vol. 94, no. 10, pp. 1–26, 2002. View at Google Scholar · View at Scopus